DHRS13

Across TCGA pan-cancer cohorts, DHRS13 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated DHRS13 data layer compared with 20 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher DHRS13 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DHRS13 expression acts as an unfavorable survival marker.

OV, LIHC, and SCLC are the cancer types where DHRS13 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.010	0.844	<.001	36	view →
LIHC	OS	Median	All	0.011	0.784	<.001	24	view →
SCLC	OS	Median	All	0.055	0.708	<.001	12	view →
STAD	OS	Median	III,IV	0.075	0.629	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

DHRS13–OV (OS)

Open the OV breakdown →